Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618745 | 0.89 | SFRP1 (0.55) | SFRP1ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL4615836 | 0.87 | HTR2A (0.41) | SFRP1ALDH1A1POLBMAPTHTR2A | |
| SCHEMBL4617748 | 0.85 | SFRP1 (0.46) | SFRP1ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL4616698 | 0.78 | SFRP1 (0.72) | SFRP1ALDH1A1POLBHSD17B10 | |
| SCHEMBL4618045 | 0.76 | ALDH1A1 (0.60) | SFRP1ALDH1A1SMN1; SMN2POLBMAPT | |
| SCHEMBL10179490 | 0.76 | MMP2 (0.49) | HTR2AHTR6HSD11B1PSIP1 | |
| SCHEMBL4618210 | 0.76 | SFRP1 (0.50) | SFRP1SMN1; SMN2 | |
| SCHEMBL4617002 | 0.76 | SFRP1 (0.42) | SFRP1ALDH1A1HTR2AHTR2CHSD11B1 | |
| SCHEMBL4446851 | 0.76 | CTSB (0.40) | ALDH1A1POLBMAPTHSD17B10TDP1 | |
| SCHEMBL11043129 | 0.75 | CA2 (0.41) | SMN1; SMN2MAPTHTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885ALDH1A1 1865/4885SMN1; SMN2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.